期刊名称：MABS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
In January of 2009 mAbs, the first international peer-reviewed journal of its kind to focus exclusively on monoclonal antibodies, was launched. We believe that this is an excellent time to start the journal because of the increasing focus on mAbs as therapeutics. There has been a rapid increase in mAb R&D by academia, government and industry located world wide. Novel mAb therapeutics are entering clinical study by commercial sponsors at a record pace (Figure 1) that is predicted to continue well into the future. MAbs have proven successful in the clinic (Table 1). In addition, a global market has emerged for the products - several novel mAbs not yet available in the US or EU are now approved in China.
mAbs is indexed in:
Medline/PubMed, PubMed Central, Science Citation Index Expanded, Biotechnology Citation Index, Biological Abstracts, Biosis Previews, Scopus
Instructions to Authors
Online Submission
mAbs utilizes an online submission and tracking system designed to provide a better, more efficient service to authors.
• Authors can submit manuscripts online from anywhere in the world.
• Authors can track their manuscript through the peer review process.
• Author files are automatically converted into a PDF (Portable Document Format) file and submissions are acknowledged by email.
• Editors and reviewers access the PDF files on the website.
Click here to submit your manuscript to mAbs.
Previously Submitted
mAbs recognizes that excellent papers may have been erroneously rejected by other journals. We will reconsider papers that have been rejected by Nature, Science, Nature Medicine, Nature Cell Biology, Cell, Cancer Cell, Cell Metabolism, Developmental Cell, NEJM, Lancet, Genes & Development and some other journals in the original format of those journals, thus saving the authors effort and time. Authors are encouraged to enclose the reviewers' and/or editorial comments from the journals mentioned above. This will expedite the evaluation of the article. In some instances, the article may be accepted based on the previous review. This allows urgent and competitive research to be published soon after submission. Papers submitted using the Select Submission Track can be accepted within 1-2 days.
Please submit your paper and contact the Editor-in-Chief with the manuscript number and a PDF with the previous review. Upon acceptance, authors should provide the paper in mAbs’s format.
Pre-submission inquiries
Pre-submission inquiries are not necessary but are welcome. These may include either an abstract or a full-length manuscript as an email attachment (Microsoft Word). Pre-submission inquiries should be emailed to the Editor-in-Chief (Janice M. Reichert).
Non-Native Speakers of English
Authors who are not native speakers of English and submit manuscripts to international journals, often receive negative comments from referees or editors about English-language usage. These problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors to take at least one or both of the following steps:
Have your manuscript reviewed for clarity by a colleague whose native language is English.
Use a service such as one of those listed at the end of our guidelines. An editor will improve the English to ensure that your meaning is clear and identify problems that require your review. Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted. Landes Bioscience accepts no responsibility for the interaction between the author and the service provider or for the quality of the work performed.
Manuscript Preparation
Types of Papers
Research Papers/Reports
Research Papers or Reports should include the following sections:
Abstract: A single paragraph of fewer than 250 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.
Key words: Include 5-10 for indexing purposes.
Introduction.
Results: Present results in a logical sequence in tables and illustrations. In the text, explain, emphasize or summarize the most important observations. Units of measurement should be expressed in accordance with Systeme International d'Unites (SI Units).
Discussion: Do not repeat in detail data given in the Results section. Emphasize the new and important aspects of the study. Relate observations to other relevant studies. On the basis of your findings (and others'), discuss possible implications/conclusions. When stating a new hypothesis, clearly label it as such.
Patients and Methods/Materials and Methods: Describe the selection of patients or experimental animals, including controls. Do not use patients' names or hospital numbers. Identify methods, apparatus (manufacturer's name and address) and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods, evaluate their advantages and limitations. Identify drugs and chemicals, including generic name, dosage and route(s) of administration.
Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.
For reagents listed in the Materials and Methods section, the company that supplied the reagent and the catalog number should be listed in parentheses; do not list the company location.
References: No more than 85.
Tables: Tables should be numbered consecutively with Arabic numerals and include descriptive titles and legends.
Figure legends.
Brief Reports
Brief Reports should constitute unusually interesting data combined with a discussion of what the data might mean, or an explanation of why the data contradicts current paradigms. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. Please include the following:
Abstract (one paragraph of fewer than 150 words)
5-10 key words for indexing purposes
Short Communications
Short Communications are aimed at publishing short, but important, breakthrough data not embedded within a complex story. The abstract should not be longer than 120 words. The paper should be structured as a research paper (see above), but without the headings and subheadings. No more than 50 references and no more than 4500 words altogether.
Reviews
Reviews should be recognized as scholarly by specialists in the field being covered, but should also be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose. Please avoid excessive jargon and technical detail. Reviews should capture the broad developments and implications of recent work. The opening paragraph should make clear the general thrust of the review and provide a clear sense of why the review is now particularly appropriate. The concluding paragraph should provide the reader with an idea of how the field may develop or future problems to overcome, but should not summarize the article. To ensure that a review is likely to be accessible to as many readers as possible, it may be useful to ask a colleague from another discipline to read the review before submitting it. Reviews should include an abstract of 150 words and should cite no more than 150 references. Please include 5-10 key words for indexing purposes.
Commentaries and Views
Commentaries and Views may be short and focused opinion articles, commentaries on papers recently published in mAbs or elsewhere, or commentaries on significant conceptual changes, important trends or new directions in the field. These may include figures and up to 30 references. Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Point of View
For Points of View articles (auto-commentary), the Editor will solicit authors of the most significant recent and forthcoming papers, published elsewhere, to provide a short summary with additional insights, new interpretations or speculation on the relevant topic. These manuscripts may include data or models which, due to space limitations, were not included or discussed in the original paper. In other words, the authors may provide biased and uncensored points of views, complementing their article. As with other papers published in mAbs, Points of View will appear online, in print and on Medline/PubMed. Points of View will appear simultaneously, or very soon after, publication of the original paper.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Meeting Reports
Meeting Reports are summaries of presentations from recent meetings in the field. Authors are encouraged to contact the Editor-in-Chief with proposals for meeting reports. Also, please contact the meeting organizers to verify that reports will be permitted. Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Article Addenda
Addenda are essentially an auto-commentary. The Editor or Editorial Board will solicit authors of the most significant recent and forthcoming papers, published elsewhere, to provide a short summary with additional insights, new interpretations or speculation on the relevant topic. These manuscripts may include data or models, which due to space limitations were not included or discussed in the original paper. In other words, the authors may provide biased and uncensored points of views, complementing their article. As with other papers published in mAbs, Addenda will appear online and in print. Addenda will appear simultaneously, or very soon after, publication of the original paper. The typical length of an addendum will be approximately 500-1,000 words and may include up to 30 references. There will be no page charges for Article Addenda and you are encouraged to include figures; however, please note the journal policy regarding color charges below.
Please include the following:
• Abstract (one paragraph of fewer than 150 words)
• 5-10 key words for indexing purposes
• The citation for the original article including the full author list, title of article and journal information should be included on the title page.
Organization
All manuscripts should be in English. Please ensure that manuscripts are clear, concise and grammatically correct.
Text should be prepared in MS Word, double-spaced, with page numbers throughout.
Organize manuscripts in the following manner:
• Title page, including titles, author's names (first, MI, last) and affiliations
• 5-10 key words (for indexing purposes)
• Acknowledgments
• A list of abbreviations and acronyms used throughout the text
• A running title of no more than 50 characters in length
• Text (length and organization depends upon type of paper)
• An abstract, the primary goal of which is to make the general significance and conceptual advance of the work clearly accessible to a broad readership. (References should not be cited in the abstract.)
• References
• Tables (with descriptive titles and legends)
• Figure legends
There are no word limits for papers published, however, accepted manuscripts are published with the understanding that page and color charges will be assessed. Please see the section, Page and Color Charges below.
If your paper is to be published in a journal indexed by PubMed/Medline, the citation of your article will be sent to PubMed within one week of acceptance; therefore, please ensure that all information is correct.
Text Files and Tables
Please save text and table files as MS Word documents. Save tables in a file separate from text. Figure legends, however, should be at the end of the manuscript as text. Tables will be reformatted during production and therefore should only be minimally formatted in your text file.
Figures
Figures should be as small and simple as clarity permits. Unnecessary figures and panels in figures should be avoided: data presented in small tables or histograms, for instance, can generally be stated briefly in the text instead. Avoid unnecessary complexity, coloring and excessive detail. Figures should not contain more than one panel unless the parts are logically connected. Where possible, text, including keys to symbols, should be provided in the text of the figure legend rather than on the figure itself. Any image processing should be explained clearly in the Materials and Methods section of your manuscript.
To aid in the processing and turnaround of issues, we ask that authors please adhere to the following figure guidelines. Authors will be asked to revise details and images if they do not adhere to the figure protocols.
Guidelines for Figure Preparation
Image presentation
(These guidelines for image presentation are adapted from the “Instructions for Authors” that are posted on the Journal of Cell Biology web site, and are included here with permission).
As you prepare your figures, please adhere to the following guidelines to accurately present your data:
1. No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
2. The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend.
3. Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including the background. Non-linear adjustments must be disclosed in the figure legend.
A more detailed discussion of image presentation can be found at the following URL: http://jcb.rupress.org/content/166/1/11.full (Rossner and Yamada, J. Cell Biol. 166:11–15)
Resolution
All submitted images must be of high quality and have resolutions of at least 300 dpi ready for print.
Formats
We require figures in electronic format. Please do not send PowerPoint, MS Word, presentation, or paint files as they are inadequate for the creation of high quality images. Much of the information contained in PowerPoint or other file types is lost or skewed in the conversion of images. Figures should be provided as TIFF, Photoshop, EPS or high resolution PDF files. Compatible graphic art programs are Adobe Illustrator and Adobe Photoshop.
Figure size
Figures should be submitted at the size they are to be published. Maximum width = 7.1667 in. Maximum height = 9.6663 in.
For multi-panel figures (such as figure 1a, 1b, 1c, etc), each panel should be assembled into one image file. Do not include separate panels on multiple pages, i.e. A, B, C and D should all fit on one page. Each panel should be sized so that the figure as a whole can be reduced by the same amount and reproduced on the printed page at the smallest size at which essential details, including type, are visible and readable.
Color mode
Save all color figures in CMYK mode at 8 bits/channel. Layering type directly over shaded or textured areas and using reversed type (white lettering on a colored background) should be avoided.
Type
Please be sure to embed all fonts. Use a sans serif font such as Helvetica. The font size should be no greater than 9 pt. and no smaller than 6 pt; however, panel labels (A, B, C) should be 15 pt. uppercase (not bold). Lettering in figures (labeling of axes and so on) should be in lowercase type, with the first letter capitalized and no full stop. Please keep font size relatively the same throughout the figures so as to avoid scaling issues. Also note that readability suffers if type is layered over a pattern or color other than white or black.
Units
Units should have a single space between the number and the unit, and follow SI nomenclature or the nomenclature common to a particular field. Thousands should be separated by commas (1,000). Unusual units or abbreviations should be defined in the legend. Please use the proper microsymbol (denoting a factor of one millionth) rather than a lower case u.
References
Include in the reference list only those articles that have been published or are in press. Unpublished data or personal communications must be cited within the text.
Please use "et al." after listing the first six authors. Do not use "et al." if there are less than six authors.
The list of references should be numbered consecutively according to the first time mentioned within the article. Cite only the number assigned to the reference:
Correct: according to Jones.1
Incorrect: according to Jones1.
Correct: noted by Smith et al.1
Incorrect: Smith et al (1).
When referring the reader to specific references as part of a sentence please state:
Correct: For a review see refs. 20-25.
Incorrect: For a review see 20-25
Journal References
• The reference format is the same for all of our journals. You may download the output style for Cell Cycle from Endnotes.
• Abbreviate journal names according to the style used in Index Medicus or a comparable source and omit punctuation after journal titles. Spell out foreign or less commonly known journal names.
• If possible, please include the PMID and DOI at the end of the reference, following the page numbers.
• [Author's last name] [Author's initials], [First six author's last names followed by their initials]. [Title of article with only the first word capitalized]. [Journal's standard abbreviated name] [Year]; [Volume (number)]:[Inclusive pages]; [PMID]; [DOI].
∗ For Example:
° Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2010; 2:181-9; PMID: 20150767; DOI: 10.4161/mabs.2.2.11158.
° Abrams SL, Steelman LS, Shelton JG, Wong EWT, Chappell WH, Basecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9: 1781 – 1791; PMID: 20436278; DOI: 10.4161/cc.9.9.11483.
Book References
• [Author's last name] [Author's initials], [Other authors' last names followed by initials]. [Chapter title]. In: [Editor's last name] [Editor's initials], ed(s). [Book Title]. [Number of edition]. [City]:[Publisher], [Year]:[Inclusive pages].
∗ For Example:
° Ozoren N, El-Diery WS. Introduction to cancer genes and growth control. In: Ehrlic M, ed. DNA Alterations in Cancer: Genetic and Epigenetic Changes. Natick, MA: Eaton Publishing, 2000:3-43.
Supplementary Files
The following fees apply for any supplementary material posted with a manuscript. A $100 fee is assessed for all text, figures and/or tables. Supplementary movies carry a rate of $150 for the first five movie files and $50 for each subsequent movie file. Fees will be outlined on the publication charge form authors receive with galley proofs.
Please provide supplementary material in the following formats:
• Text: MS Word file
• Table/Data: MS Word file or Excel file
• Figures: Please provide figures in a MS Word file or in a PPT file, clearly labeled with figure legends below them.
• Video Files: Video submissions for viewing online should be Audio Video Interleave (.avi), MPEG (.mpg), or Quick Time (.qt, .mov).
° AVI files can be displayed via Windows Media Player (http://www.microsoft.com/windows/windowsmedia/players.aspx); MPEG files can be displayed via Windows Media Player; Quick Time files require Quick Time software (free) from Apple (http://www.apple.com/quicktime/download/index.html)
° Videos should be brief whenever possible (<2-5 minutes). Longer videos will require longer download times and may have difficulty playing online. Videos should be restricted to the most critical aspects of your research. A longer procedure can be restructured as several shorter videos and submitted in that form.
° It is advisable to compress files to use as little bandwidth as possible and to avoid overly long download times. Video files should be no larger than 5 megabytes. This is a suggested maximum. If files are larger, please contact the .
° A caption giving a brief overall description of the video content should be provided for each video.
° If your paper is accepted for publication you may wish to supply the editorial office with several different resolutions of your video files. This will allow viewers with slower connections to download a lower resolution version of your video.
Please also provide ALL files in one PDF file. Links to supplementary data will be included in the PDF of the published manuscript and in the online abstract.
Publication Charges
Page Charges
Page charges apply at a rate of $100 per page or partial page used for articles classified as Reports, Technical Papers, Brief Reports and Short Communications.
Color Charges
Please note that color charges are assessed separately from page charges and will be added to the total amount of page charges assessed. Publication of color images is free for the online version of the journal, but carries a page charge of $340 for the first page and $150 for each additional page in the print edition. Authors may choose to convert color images to grayscale for the print edition of their manuscript in order to eliminate color charges. If this option is selected, authors should provide replacement figure legend text at the galley proof stage if the original legends contain references to color.
Supplementary File Charges
Supplementary fees apply for any supplementary material posted with a manuscript. A $100 fee is assessed for all text, figures and/or tables. Supplementary movies carry a rate of $150 for the first five movie files and $50 for each subsequent movie file.
Under exceptional circumstances, where there are no funds to cover page charges and articles cannot be reduced in size, authors may appeal directly to the Editor for page charges to be waived. This appeal must be supported by a letter signed by a finance official at the author’s institution, confirming that no funds are available to cover page charges.
Page Proofs
Page proofs will be sent to the author via email. Page proofs should be returned within two working days, preferably by email. Corrections should be marked on the actual proof and provided in a numbered list. Lengthy additions should be avoided, but where necessary should be provided in a MS Word file, with explicit instructions regarding placement.
Reprints/Pre-Prints
A reprint and pre-print order form will be sent, along with an outline of publication charges, to authors via email with page proofs.
International Edit
International Edit
A truly unique service – quality, affordable editing with a personal touch.
We are 10 career editors – unlike our competitors, we do NOT send your paper to a freelancer. This ensures careful, consistent, and confidential editing.
More than copyediting. A sentence that is perfect grammatically may still not make your point. We work with you to get it right.
Have your own personal editor for life – email us about anything, we’re here to help.
Free follow-up with every edit.
Authors do not pay until after receiving and reviewing their edit.
No registration. No hassle. We never have access to any of your personal information.
Mention code 10LN20 for a 20% discount.
Cover Image Submissions
mAbs publishes cover illustrations that are taken from articles in each issue, or that are designed to accompany an accepted article.
The cover illustration should be scientifically interesting and visually attractive. The illustration need not be a figure from the paper, but should be closely related to the subject of the paper. If you are interested in submitting a figure for use as the cover of mAbs, please email a high-resolution version of your image, conforming to the specifications below, and an explanatory caption of 50-60 words to the
All potential cover images should be sized to fit on a singler letter size (8.5" x 11") page. Please remove all text, captions, etc. from the image. If you have variations of the image, you may send additional files. Please send no more than two alternate versions.
Accepted formats and resolution:
• PSD (Adobe Photoshop: if graphics are built with layers, do not flatten), 300 dpi, CMYK at 100% size.
• TIF, 300 dpi, CMYK at 100% size
• JPG, 300 dpi highest quality, CMYK at 100% size.
• EPS (scalable vector line art)
• AI (Adobe Illustrator)
Editorial Board
Editor-in-Chief
Janice M. Reichert
Boston, MA, US
Associate Editor
Alain Beck
Centre d'Immunologie Pierre Fabre (CIPF)
St Julien-en-Genevois, FR
Editorial Board
Gregory P. Adams
Fox Chase Cancer Center
Philadelphia, PA, US
S. Robert Adamson
Nasimul Ahsan
W.G. "Bill" Hefner VA Medical Center
Salisbury, NC, US
Ashraf Amanullah
Genentech, Inc.
Oceanside, CA, US
Laurent P. Audoly
Pieris AG
Freising, DE
Joseph P. Balthasar
University of New York at Buffalo
Buffalo, NY, US
Detlev Biniszkiewicz
Novartis Institutes for Biomedical Research
Cambridge, MA, US
Sally Bolmer
Human Genome Sciences
Rockville, MD, US
Pavel V. Bondarenko
Amgen
Thousand Oaks, CA, US
Arindam Bose
Pfizer
New London, CT, US
Andrew Bradbury
Los Alamos National Laboratory
Los Alamos, NM, US
John C. Byrd
The Ohio State University
Columbus, OH, US
Paul J. Carter
Genentech
Oceanside, CA, US
Michael Chartrain
Merck & Co., Inc.
Rahway, NJ, US
Vijay K. Chaudhary
University of Delhi South Campus
Delhi, IN
Mike Clark
Cambridge University
Cambridge, UK
Ralph Clynes
Columbia University
New York, NY, US
Nathalie Corvaia
Centre d'Immunologie Pierre Fabre (CIPF)
St Julien-en-Genevois, FR
Graeme Currie
Regeneron Pharmaceuticals
Tarrytown, NY, US
John R. Desjarlais
Xencor, Inc.
Monrovia, CA, US
Dimiter S. Dimitrov
National Institutes of Health
Frederick, MD, US
Donald Drakeman
Advent Venture Partners
London, UK
Stefan Dübel
Technische Universität Braunschweig
Braunschweig, DE
Martin Glennie
University of Southampton
Southampton, UK
David Glover
MedCell Bioscience Ltd.
Cambridge, UK
Iqbal S. Grewal
Seattle Genetics, Inc.
Bothell, WA, US
Yajun Guo
PLA General Hospital Cancer Center
Beijing, CN
Sherif Hanala
Global BioFocus LLC
San Francisco, CA, US
Raffit Hassan
National Cancer Institute
Bethesda, MD, US
P. Mark Hogarth
Burnet Institute
Heidelberg, AU
Hennie R. Hoogenboom
BioQuest BV
Maastricht, NL
James S. Huston
EMD Serono
Billerica, MD, US
Roy Jefferis
University of Birmingham
Birmingham, UK
Denny Kraichely
Johnson & Johnson/Centocor
New Brunswick, NJ, US
Gaurav Laroia
Merck & Co., Inc.
Whitehouse Station, NJ, US
Marie-Paule Lefranc
Université Montpellier II
Montpellier, FR
Nils Lonberg
Brisol-Myers Squibb/Medarex
Princeton, NJ, US
Henry Lowman
NGM Biopharmaceuticals
San Francisco, CA, US
James D. Marks
University of California at San Francisco
San Francisco, CA, US
John L. Marquardt, Jr.
Finnegan, Henderson, Farabow, Garret & Dunner, L.L.P.
Washington, D.C., US
R.A. Mashelkar
National Chemical Laboratory
Pune, IN
Richard Mason
BTG Group
London, UK
Kiran Mazumdar Shaw
Biocon Ltd.
Bangalore, IN
John McCafferty
Cambridge University
Cambridge, UK
Sherie Morrison
University of California at Los Angeles
Los Angeles, CA, US
Jan Mueller-Berghaus
Paul-Ehrlich-Institiute, Federal Agency for Sera and Vaccines
Langen, DE
Bilikallahalli Muralidhara
Pfizer
Chesterfield, MO, US
Dario Neri
Swiss Federal Institute of Technology Zurich
Zurich, CH
Jane Osbourn
MedImmune, Inc.
Cambridge, UK
Gilles Paintaud
Université François-Rabelais
Tours, FR
Paul Parren
Genmab
Utrecht, NL
Ira Pastan
National Institutes of Health
Bethesda, MD, US
André Pelegrin
Institut de Recherche en Cancérologie de Montpellier
Montpellier, FR
Andreas Plückthun
University of Zurich
Zurich, CH
Leonard Presta
Merck & Co., Inc.
Palo Alto, CA, US
Vijay Ramakrishnan
Pikamab, Inc.
Menlo Park, CA, US
Mitsuo Satoh
Kyowa Hakko Kirin
Tokyo, JP
Christian K. Schneider
Paul-Ehrlich-Institiute, Federal Agency for Sera and Vaccines
Langen, DE
Jamie Scott
Simon Fraser University
Burnaby, BC, CA
Marjorie Shapiro
US Food and Drug Administration
Washington, DC, US
Sachdev Sidhu
University of Toronto
Toronto, ON, CA
Arne Skerra
Technische Universität München
Munich, DE
Jean-Luc Teillard
Centre de Recherche des Cordeliers/INSERM
Paris, FR
Jan ter Meulen
Merck & Co., Inc.
North Wales, PA, US
Pablo Umana
Glycart Biotechnology AG (Roche Group)
Zurich, CH
Jan van de Winkel
Genmab
Copenhagen, DK
E. Sally Ward
University of Texas Southwestern Medical Center
Dallas, TX, US
Hervé Watier
Université François-Rabelais/CNRS
Tours, FR
Louis M. Weiner
Georgetown University Medical Center
Washington, DC, US
Gregory Winter
MRC Laboratory of Molecular Biology
Cambridge, UK
K. Dane Wittrup
Massachusetts Institute of Technology
Boston, MA, US
Clive Wood
Bayer
Pittsburgh, PA, US
Jenny M. Woof
University of Dundee Medical School
Dundee, UK
Herren Wu
MedImmune
Cambridge, UK
Thierry Wurch
Institut de Recherche Pierre Fabre
St Julien-en-Genevois, FR
Bodi Zhang
Tufts University
Boston, MA, US
| 
刊名字顺( Alphabetical List of Journals):
返回页首 
